Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (VIR) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · VIR · as of Sep 30, 2025
Ownership Breakdown
224
Institutional Holders
▼ 2 vs Q2
$611.07M
Total Inst. Value
▲ $52.27M vs Q2
168.65M
Shares Outstanding
freeFloat 76.36%
107.01M
13F Shares Held
▼ 3.83M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
VIR largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SB INVESTMENT ADVISERS (UK) LTD biological products, (no diagnostic substances) | 16.68M | 12.05% | 12.05% | $95.27B | Nov 14, 2025 | — held |
BLACKROCK, INC. biological products, (no diagnostic substances) | 15.97M | 11.53% | 11.53% | $91.18B | Nov 12, 2025 | ▼ 185.5K |
ARCH VENTURE MANAGEMENT, LLC biological products, (no diagnostic substances) | 12.92M | 9.33% | 9.33% | $73.75B | Nov 14, 2025 | — held |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 12.80M | 9.24% | 9.24% | $73.08B | Nov 7, 2025 | ▼ 427.7K |
STATE STREET CORP biological products, (no diagnostic substances) | 5.24M | 3.79% | 3.79% | $29.93B | Nov 14, 2025 | ▼ 13.4K |
FMR LLC biological products, (no diagnostic substances) | 3.64M | 2.63% | 2.63% | $20.77B | Nov 13, 2025 | ▲ 78.5K |
DIMENSIONAL FUND ADVISORS LP biological products, (no diagnostic substances) | 2.98M | 2.15% | 2.15% | $17.01B | Nov 12, 2025 | ▼ 29.1K |
MORGAN STANLEY biological products, (no diagnostic substances) | 2.69M | 1.94% | 1.94% | $15.35B | May 27, 2026 | ▲ 1.06M |
ORBIMED ADVISORS LLC biological products, (no diagnostic substances) | 2.38M | 1.72% | 1.72% | $13.59B | Nov 14, 2025 | — held |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 2.25M | 1.62% | 1.62% | $12.83B | Nov 12, 2025 | ▼ 6.2K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
20
Increased
+4.08M shares0
New Positions
first time holders23
Decreased
−5.51M shares0
Sold Out
fully exitedNet shares change (top 50)
1.43M
+4.08M / −5.51M
Net new holders
-3
0 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
VIR insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
13
Buy transactions
6
Sell transactions
2.17
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Napolitano Janet director | Jun 1, 2026 | Sale | 3,200 | $9.45 | $30.2K | 21.2K | Form 4 ↗ |
Sabatini Brent SVP, Chief Accounting Officer | Jun 1, 2026 | Sale | 379 | $9.45 | $3.6K | 61.9K | Form 4 ↗ |
Sigal Charles Elliott director | May 27, 2026 | Award | 8,000 | — | — | 39.8K | Form 4 ↗ |
Sigal Charles Elliott director | May 27, 2026 | Award | 16,000 | $9.10 | $145.6K | 16.0K | Form 4 ↗ |
Napolitano Janet director | May 27, 2026 | Award | 8,000 | — | — | 24.4K | Form 4 ↗ |
Napolitano Janet director | May 27, 2026 | Award | 16,000 | $9.10 | $145.6K | 16.0K | Form 4 ↗ |
MORE ROBERT J director | May 27, 2026 | Award | 8,000 | — | — | 48.7K | Form 4 ↗ |
MORE ROBERT J director | May 27, 2026 | Award | 16,000 | $9.10 | $145.6K | 16.0K | Form 4 ↗ |
Hatfield Jeffrey S. director | May 27, 2026 | Award | 8,000 | — | — | 39.8K | Form 4 ↗ |
Hatfield Jeffrey S. director | May 27, 2026 | Award | 16,000 | $9.10 | $145.6K | 16.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Vir Biotechnology, Inc. (VIR) is primarily owned by institutional investors, who hold approximately 63.5% of total shares outstanding. Company insiders own approximately 23.64%, while retail and public investors account for the remaining 12.91%.
The largest institutional shareholder of Vir Biotechnology, Inc. is SB INVESTMENT ADVISERS (UK) LTD, holding approximately 16.68 million shares — equal to 12.05% of outstanding shares — as of September 30, 2025.
A total of 224 institutional investors currently hold VIR stock, with a combined institutional value of approximately $611,069,760 as of the most recent 13F filing period.
Frequently asked questions
VIR ownershipVir Biotechnology, Inc. (VIR) is primarily owned by institutional investors, who hold approximately 63.5% of shares. The largest shareholder is SB INVESTMENT ADVISERS (UK) LTD with a 12.05% stake. Company insiders hold 23.64%. Data sourced from SEC Form 13F as of September 30, 2025.